SCHEMBL2969767

SCHEMBL2969767

O=C(O)C1CC2CCC1O2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
GMNN O75496 1/20 0.44
LMNA P02545 1/20 0.44
PMP22 Q01453 1/20 0.44
TFPI2 P48307 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
THPO P40225 1/20 0.44
RIPK1 Q13546 3/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
GABRR1 P24046 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PPM1B O75688 1/20 0.34
PTPN1 P18031 1/20 0.34
PPP1CC P36873 1/20 0.34
PSMB8 P28062 1/20 0.33
PSMB5 P28074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8239877 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL13795024 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL3465697 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL34461967 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL3259183 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL9376106 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL4738730 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL8246038 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL8067270 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL4738727 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110114349-B Thiophene derivatives as antiviral agents 埃尼奥制药公司 2022-03-15 CN claimed
WO-2008077809-A1 PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-07-03 WO claimed
US-20080154043-A1 PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US claimed
US-12577234-B2 Antagonists of the muscarinic acetylcholine receptor M4 VANDERBILT UNIVERSITY (US) 2026-03-17 US disclosed
EP-4612150-A1 BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS Ventus Therapeutics U.S., Inc. (US) 2025-09-10 EP disclosed
US-20250257077-A1 BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2025-08-14 US disclosed
CN-115066428-B Boric acid derivatives 首药控股(北京)股份有限公司 2025-06-13 CN disclosed
CN-119613408-A Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2025-03-14 CN disclosed
CN-110914271-B Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2024-12-10 CN disclosed
CN-118791500-A 7-Oxabicyclo [2.2.1] heptane-2, 3-dicarboxylic acid derivative and preparation method and application thereof 中国药科大学 2024-10-18 CN disclosed
US-20240300974-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2024-09-12 US disclosed
US-20080154043-A1 PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US disclosed
US-20080153030-A1 Positive resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-06-26 US disclosed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO disclosed
US-20070231738-A1 Resist composition and patterning process using the same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-10-04 US disclosed
WO-2007031557-A2 ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES SPEEDEL EXPERIMENTA AG (CH) 2007-03-22 WO disclosed
US-5641784-A ADENOSINE ANTAGONISTS; TREATMENT OF NERVOUS SYSTEM DISORDERS, ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM KG (DE) 1997-06-24 US disclosed
EP-0487673-A1 NEW XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1992-06-03 EP disclosed
WO-1992000297-A1 NEW XANTHINE DERIVATIVES BOEHRINGER INGELHEIM KG (DE) 1992-01-09 WO disclosed
US-4958036-A Enantiomerically selective synthesis of certain N-substituted-2-(carbamyl 7-oxabicyclo[2.2.1]heptane-3-carboxylic acids E. R. SQUIBB & SONS, INC. (US) 1990-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257077-A1 BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS NLRP3, NLRP1, NOD1 KDM4E 2895/4885GMNN 4508/4885LMNA 1451/4885
US-20080154043-A1 PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES CYP3A7, UGT2B7, CYP1B1 KDM4E 1611/4885GMNN 2894/4885LMNA 2526/4885
US-12577234-B2 Antagonists of the muscarinic acetylcholine receptor M4 CHRM3, CHRM4, CHRM2 KDM4E 2168/4885GMNN 3300/4885LMNA 3873/4885
US-20240300974-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HSD17B7, CYP11B1, CYP11B2 KDM4E 1229/4885GMNN 3901/4885LMNA 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.